
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Perceptive Xontogeny Venture Fund
Deal Size : $63.0 million
Deal Type : Series A Financing
Neurosterix Launches with $63M to Advance Neurological Modulator Therapies
Details : The financing will support Neurosterix’s lead program, a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator for treating schizophrenia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Perceptive Xontogeny Venture Fund
Deal Size : $63.0 million
Deal Type : Series A Financing
